Imaging Technology News (ITN)

Multicenter Study Shows High Local Tumor Control After Resection with GammaTile in Newly Diagnosed Brain Metastases

GT Medical Technologies released Phase IV registry data showing that GammaTile brachytherapy, implanted at the time of surgical resection, achieved 92.3% local tumor control in newly diagnosed brain metastases after a median 12.4‑month follow‑up. The study of 51 patients reported a 7.8% cumulative incidence of leptomeningeal disease and a 9.8% rate of Grade 3 toxicity, with no radiation necrosis observed. Researchers highlighted the advantage of immediate, localized radiation in closing the treatment gap between surgery and conventional radiotherapy. Ongoing randomized trials will further define GammaTile’s comparative efficacy.